Trial Profile
A Phase I, Proof of Concept, Open Label, Escalating Dose Study to Assess the Safety, Tolerability and Immunogenicity of a Herpes Simplex Virus (HSV) Deoxyribonucleic Acid (DNA) Vaccine in Healthy Volunteers
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 08 Jun 2016
Price :
$35
*
At a glance
- Drugs Herpes simplex virus DNA vaccine (Primary)
- Indications Herpes genitalis
- Focus Adverse reactions; Proof of concept
- Sponsors Admedus
- 13 Feb 2015 Status changed from recruiting to completed, according to Australian New Zealand Clinical Trials Registry record.
- 02 Sep 2013 New trial record